FFA
VKTX icon

Frazier Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Frazier Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48
Closed -$1.16K – 665
2025
Q1 		$1.16K Hold
48
– – ﹤0.01% 515
2024
Q4 		$1.91K Hold
48
– – ﹤0.01% 511
2024
Q3 		$3.04K Hold
48
– – ﹤0.01% 635
2024
Q2 		$2.54K Sell
48
-100
-68% -$6.55K ﹤0.01% 761
2024
Q1 		$12.1K Buy
+148
New +$6.58K 0.01% 372

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Frazier Financial Advisors's VKTX Position: Q2 2025 in Review

Frazier Financial Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 48 shares — an estimated $1.16K sold.

Frazier Financial Advisors first reported a position in VKTX in Q1 2024 and held it in 5 quarters. The position peaked at $12.1K in Q1 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

  • Frazier Financial Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Frazier Financial Advisors sold 48 Viking Therapeutics shares in Q2 2025, an estimated $1.16K.
  • Frazier Financial Advisors first reported a position in Viking Therapeutics in Q1 2024 and held it in 5 quarters.
  • Frazier Financial Advisors's Viking Therapeutics position peaked at $12.1K in Q1 2024.
  • 391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Frazier Financial Advisors's 13F filing for Q2 2025, filed 28 Jul 2025.